Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SciSparc Ltd. (SPRC)
USD4.90
+0.63 (+14.75%)
IL NASDAQ Healthcare Biotechnology
Address
Tower A 6971916
Tel Aviv, IL
Tel Aviv, IL
CEO
Oz Adler
Website
scisparc.com
IPO
2021-08-30
CIK 1611746 ISIN IL0010951403
Description
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.90
+0.63 (+14.75%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
2.43
Float Shares
57.8K
Free Float %
99.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.01% | +119.46% | +11.86% | +96.20% | -50.45% | -19.85% | -83.58% | -99.70% | -99.96% | -99.96% | -99.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4.90
Quality scores
Altman Z-Score
-22.10
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-34.5% Q4'25: -56.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-8,980.7% Q4'25: +71.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,271.6% Q4'25: -576.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-1,466.5% Q4'25: +101.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-1,361.5% Q4'25: +174.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+2,031.9% Q4'25: -86.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q4'25: 0.20× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
2.88M
est: 6.28B (-100.0%)
|
1.31M
est: 6.97B (-100.0%)
|
856.0K
est: 6.56B (-100.0%)
|
| EBITDA |
-5.31M
est: -6.28B (+99.9%)
|
-6.97M
est: -6.97B (+99.9%)
|
-12.32M
est: -6.56B (+99.8%)
|
| EBIT |
-5.85M
est: -6.28B (+99.9%)
|
-7.46M
est: -6.97B (+99.9%)
|
-12.55M
est: -6.56B (+99.8%)
|
| Net Income |
-5.12M
est: 146.6K (-3,593.5%)
|
-6.28M
est: 419.2K (-1,599.1%)
|
-12.18M
est: 459.5K (-2,750.6%)
|
| SGA |
6.13M
est: 22.33B (-100.0%)
|
5.81M
est: 29.27B (-100.0%)
|
5.44M
est: 27.54B (-100.0%)
|
| EPS |
-112.95
est: 0.03 (-448,848.5%)
|
-9.72
est: 0.03 (-32,094.7%)
|
-882.64
est: 0.03 (-2,650,670.6%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.79M
OE per share TTM
-115.19
Owner's Yield
-2,458.19%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
12.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Robert Eide | 11.20M | 7.72% | 11.20M | — | 11.20M | — | IN | New York | 2020-12-09 | ↗ |
| 2 | Robert J Eide Pension Plan | 11.20M | 7.72% | 11.20M | — | 11.20M | — | OO | New York | 2020-12-09 | ↗ |
| 3 | BARCLAYS GLOBAL INVESTORS, NA. | 878.2K | 5.58% | — | 186.6K | — | 186.6K | BK | United States | 2017-04-13 | ↗ |
| 4 | Ltd. | 230.8K | 9.33% | 230.8K | — | 230.8K | — | CO | Israel | 2022-12-13 | ↗ |
| 5 | YA II PN, Ltd. | 115.5K | 9.99% | — | 115.5K | — | 115.5K | OO | Cayman Islands | 2024-03-06 | ↗ |
| 6 | Morgan Stanley | 68.1K | 0.00% | — | — | — | 68.1K | HC, CO | Delaware. | 2020-08-10 | ↗ |
| 7 | Michael Bigger | 26.2K | 4.99% | — | — | — | 26.2K | IN | Delaware | 2022-02-11 | ↗ |
| 8 | District 2 Capital Fund LP | 20.0K | 4.99% | — | — | — | 20.0K | PN | Delaware | 2022-02-11 | ↗ |
| 9 | District 2 Capital LP | 20.0K | 4.99% | — | — | — | 20.0K | PN | Delaware | 2022-02-11 | ↗ |
| 10 | District 2 GP LLC | 20.0K | 4.99% | — | — | — | 20.0K | OO | Delaware | 2022-02-11 | ↗ |
| 11 | District 2 Holdings LLC | 20.0K | 4.99% | — | — | — | 20.0K | OO | Delaware | 2022-02-11 | ↗ |
| 12 | Bigger Capital Fund GP, LLC | 6.1K | 4.99% | — | — | — | 6.1K | OO | Delaware | 2022-02-11 | ↗ |
| 13 | Bigger Capital Fund, LP | 6.1K | 4.99% | — | — | — | 6.1K | PN | Delaware | 2022-02-11 | ↗ |
| 14 | Morgan Stanley Capital Services LLC | — | 0.00% | — | — | — | — | CO | Delaware. | 2020-08-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
+3 vs prev Q
New positions
3
Closed positions
0
Increased
3
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | UBS GROUP AG | 3.1K +3.1K (+100.0%) | 11.5K +11.5K (+100.0%) | 7.75% +7.748 pp | 0.00% +0.000 pp | USD3.66 +0.0% | 1 qtrs NEW |
| 2 | STRATEGIC INVESTMENT SOLUTIONS, INC. /IL | 133.00 +133.0 (+100.0%) | 487.00 +487.0 (+100.0%) | 0.33% +0.328 pp | 0.00% +0.000 pp | USD3.65 +0.3% | 1 qtrs NEW |
| 3 | SBI SECURITIES CO., LTD. | 1.00 +1.0 (+100.0%) | 4.00 +4.0 (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD3.00 +22.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.05% | 65.5K | 0.42% |
| 2 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.01% | 60.4K | 0.33% |
| 3 | Avantis Emerging Markets Value ETF AVES | 0.01% | 96.5K | 0.36% |
| 4 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 14.0K | 0.35% |
| 5 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 340.1K | 0.33% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Zuloff-Shani Adi | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 5,528 | D | ↗ |
| 2026-03-18 | Weiss Amitay | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 11,058 | D | ↗ |
| 2026-03-18 | Vider Lior | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 3,651 | D | ↗ |
| 2026-03-18 | Sidi Liat | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 3,651 | D | ↗ |
| 2026-03-18 | Shrem Itschak | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 11,058 | D | ↗ |
| 2026-03-18 | Shay Amnon Ben | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 3,651 | D | ↗ |
| 2026-03-18 | Revach Moshe | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 3,651 | D | ↗ |
| 2026-03-18 | DAYAN ALON | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 3,651 | D | ↗ |
| 2026-03-18 | Adler Oz | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 11,058 | D | ↗ |
| 2022-03-01 | Zuloff-Shani Adi | Officer | — | — | Stock option (right to buy) | 6 | 21,294.00 | 127.8K | 0 | D | ↗ |
| 2022-03-01 | Weiss Amitay | Director | — | — | Stock option (right to buy) | 6 | 21,294.00 | 127.8K | 0 | D | ↗ |
| 2022-03-01 | Vider Lior | Director | — | — | Stock option (right to buy) | 1 | 21,294.00 | 21.3K | 0 | D | ↗ |
| 2022-03-01 | Sidi Liat | Director | — | — | Stock option (right to buy) | 1 | 21,294.00 | 21.3K | 0 | D | ↗ |
| 2022-03-01 | Shrem Itschak | Director | — | — | Stock option (right to buy) | 6 | 21,294.00 | 127.8K | 0 | D | ↗ |
| 2022-03-01 | Shay Amnon Ben | Director | — | — | Stock option (right to buy) | 1 | 21,294.00 | 21.3K | 0 | D | ↗ |
| 2022-03-01 | Revach Moshe | Director | — | — | Stock option (right to buy) | 1 | 21,294.00 | 21.3K | 0 | D | ↗ |
| 2022-03-01 | Adler Oz | Officer | — | — | Stock option (right to buy) | 6 | 21,294.00 | 127.8K | 0 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-62.8K
Shares Outstanding
57.8K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Oz Adler | Chief Executive Officer & Chief Financial Officer | 336.0K | male |
| Adi Zuloff-Shani | Chief Technologies Officer | 290.0K | — |
| Amitai Weiss | President & Director | 185.0K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPRC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
